buy speculative objective growth price target 29 biotechnology 5 7 99 16 75 52 week range 28 13 year end december fiscal yr eps p e 1998 0 51 nm 1999e 39 2000e 32 3x roe book value 8 74 est 3 shares outs 18 6 million float 15 market cap 311 s&p 500 a78 1345 00 1999 27 9x todd r nelson ph d trnelson dainrauscher com 612 371 2710 may protein design labs inc nasdaq pdli initiating coverage with a rating investment highlights zenapax poised for significant revenue as penetra tion increases we believe increased sales will be driven by continued mar ket penetration drivers of this in our view are expected to the drug s large benefit toxicity ratio its recent launch europe and broadening markets worldwide based on roche users estimate period 2004 at 50 79 1 mil lion 104 133 149 168 de sign lab
